Uncontrolled, Multicenter, Dose Finding, Safety and Pharmacokinetic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-IR/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination with Anticancer Therapies in Patients with Advanced Solid Tumors

Trial Profile

Uncontrolled, Multicenter, Dose Finding, Safety and Pharmacokinetic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-IR/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination with Anticancer Therapies in Patients with Advanced Solid Tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs AVE 1642 (Primary) ; Docetaxel; Doxorubicin; Erlotinib; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top